Krebs Net Income From Continuing Ops vs Operating Income Analysis

KREBSBIO

104.14 8.79 7.78%

Krebs Biochemicals financial indicator trend analysis is infinitely more than just investigating Krebs Biochemicals and recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Krebs Biochemicals and is a good investment. Please check the relationship between Krebs Biochemicals Net Income From Continuing Ops and its Operating Income accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Krebs Biochemicals and. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.

Net Income From Continuing Ops vs Operating Income

Net Income From Continuing Ops vs Operating Income Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Krebs Biochemicals and Net Income From Continuing Ops account and Operating Income. At this time, the significance of the direction appears to have very strong relationship.

The correlation between Krebs Biochemicals' Net Income From Continuing Ops and Operating Income is 0.83. Overlapping area represents the amount of variation of Net Income From Continuing Ops that can explain the historical movement of Operating Income in the same time period over historical financial statements of Krebs Biochemicals and, assuming nothing else is changed. The correlation between historical values of Krebs Biochemicals' Net Income From Continuing Ops and Operating Income is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Income From Continuing Ops of Krebs Biochemicals and are associated (or correlated) with its Operating Income. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Operating Income has no effect on the direction of Net Income From Continuing Ops i.e., Krebs Biochemicals' Net Income From Continuing Ops and Operating Income go up and down completely randomly.

Correlation Coefficient

0.83

Relationship Direction	Positive
Relationship Strength	Strong

View All Relationships

Net Income From Continuing Ops

Operating Income

Operating Income is the amount of profit realized from Krebs Biochemicals and operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Krebs Biochemicals and is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.

Most indicators from Krebs Biochemicals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Krebs Biochemicals and current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Krebs Biochemicals and. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.

The current Selling General Administrative is estimated to decrease to about 5.7 M. The current Issuance Of Capital Stock is estimated to decrease to about 61.2 M

	2021	2022	2023	2024 (projected)
Total Operating Expenses	195.1M	488.0M	46.2M	43.8M
Cost Of Revenue	737M	256.8M	613.0M	342.2M

Total Operating Expenses Cost Of Revenue

Krebs Biochemicals fundamental ratios Correlations

	Common Stock Shares Outstanding	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Common Stock	Short Term Debt	Current Deferred Revenue	Retained Earnings	Intangible Assets	Other Liab
Common Stock Shares Outstanding		0.09	0.61	0.59	0.17	-0.85	0.85	0.49	0.3	0.0	0.49	-0.64	-0.1	-0.51	0.88	-0.34	0.3	0.32	0.88	-0.54	0.97	-0.26	0.2	-0.89	0.67	0.82
Total Assets	0.09		0.27	0.12	0.01	0.16	0.39	0.17	0.2	-0.13	0.84	0.46	-0.25	0.74	0.46	0.31	0.33	0.33	0.44	0.7	0.22	0.02	-0.31	-0.18	-0.19	-0.08
Short Long Term Debt Total	0.61	0.27		0.87	0.07	-0.78	0.54	0.95	0.23	-0.19	0.65	-0.05	-0.43	-0.03	0.78	-0.1	0.11	0.67	0.76	-0.11	0.69	-0.26	0.09	-0.87	0.31	0.54
Other Current Liab	0.59	0.12	0.87		0.0	-0.74	0.52	0.88	0.05	-0.21	0.5	-0.14	-0.4	-0.14	0.69	-0.18	0.16	0.4	0.66	-0.24	0.69	-0.31	0.01	-0.79	0.53	0.66
Total Current Liabilities	0.17	0.01	0.07	0.0		-0.31	0.14	-0.04	0.55	-0.07	-0.05	-0.29	0.14	-0.23	0.07	0.68	-0.04	-0.11	0.3	0.17	0.07	0.79	0.11	-0.13	-0.23	-0.17
Total Stockholder Equity	-0.85	0.16	-0.78	-0.74	-0.31		-0.65	-0.7	-0.33	0.12	-0.32	0.61	0.21	0.61	-0.75	0.2	-0.13	-0.39	-0.79	0.57	-0.81	0.15	-0.27	0.91	-0.55	-0.71
Property Plant And Equipment Net	0.85	0.39	0.54	0.52	0.14	-0.65		0.41	0.24	-0.04	0.73	-0.53	-0.05	-0.17	0.87	-0.27	0.46	0.36	0.84	-0.24	0.83	-0.18	0.11	-0.81	0.58	0.62
Net Debt	0.49	0.17	0.95	0.88	-0.04	-0.7	0.41		-0.02	-0.21	0.55	0.03	-0.43	0.01	0.67	-0.17	-0.07	0.62	0.62	-0.14	0.57	-0.25	0.04	-0.76	0.24	0.46
Accounts Payable	0.3	0.2	0.23	0.05	0.55	-0.33	0.24	-0.02		-0.06	0.19	-0.28	-0.18	-0.18	0.26	0.54	0.21	0.08	0.42	0.18	0.29	0.09	-0.04	-0.32	0.03	0.06
Cash	0.0	-0.13	-0.19	-0.21	-0.07	0.12	-0.04	-0.21	-0.06		-0.22	-0.16	0.86	-0.1	-0.18	-0.31	-0.32	-0.03	-0.17	-0.01	-0.03	-0.05	0.48	0.13	0.27	0.04
Non Current Assets Total	0.49	0.84	0.65	0.5	-0.05	-0.32	0.73	0.55	0.19	-0.22		0.16	-0.37	0.46	0.8	0.0	0.43	0.53	0.74	0.32	0.59	-0.18	-0.21	-0.64	0.15	0.31
Non Currrent Assets Other	-0.64	0.46	-0.05	-0.14	-0.29	0.61	-0.53	0.03	-0.28	-0.16	0.16		-0.31	0.81	-0.3	0.32	-0.13	0.12	-0.34	0.71	-0.48	0.05	-0.34	0.42	-0.62	-0.5
Cash And Short Term Investments	-0.1	-0.25	-0.43	-0.4	0.14	0.21	-0.05	-0.43	-0.18	0.86	-0.37	-0.31		-0.14	-0.34	-0.23	-0.24	-0.23	-0.3	-0.04	-0.21	0.29	0.45	0.3	0.14	-0.13
Net Receivables	-0.51	0.74	-0.03	-0.14	-0.23	0.61	-0.17	0.01	-0.18	-0.1	0.46	0.81	-0.14		-0.13	0.27	0.11	0.23	-0.19	0.87	-0.37	0.1	-0.33	0.31	-0.48	-0.47
Non Current Liabilities Total	0.88	0.46	0.78	0.69	0.07	-0.75	0.87	0.67	0.26	-0.18	0.8	-0.3	-0.34	-0.13		-0.21	0.35	0.51	0.97	-0.22	0.93	-0.3	0.04	-0.9	0.48	0.7
Inventory	-0.34	0.31	-0.1	-0.18	0.68	0.2	-0.27	-0.17	0.54	-0.31	0.0	0.32	-0.23	0.27	-0.21		-0.11	-0.19	-0.01	0.66	-0.32	0.65	-0.34	0.25	-0.61	-0.58
Other Current Assets	0.3	0.33	0.11	0.16	-0.04	-0.13	0.46	-0.07	0.21	-0.32	0.43	-0.13	-0.24	0.11	0.35	-0.11		0.26	0.31	0.04	0.37	-0.21	0.11	-0.3	0.41	0.47
Other Stockholder Equity	0.32	0.33	0.67	0.4	-0.11	-0.39	0.36	0.62	0.08	-0.03	0.53	0.12	-0.23	0.23	0.51	-0.19	0.26		0.46	0.09	0.42	-0.31	0.48	-0.53	0.22	0.36
Total Liab	0.88	0.44	0.76	0.66	0.3	-0.79	0.84	0.62	0.42	-0.17	0.74	-0.34	-0.3	-0.19	0.97	-0.01	0.31	0.46		-0.17	0.91	-0.13	0.07	-0.88	0.4	0.63
Total Current Assets	-0.54	0.7	-0.11	-0.24	0.17	0.57	-0.24	-0.14	0.18	-0.01	0.32	0.71	-0.04	0.87	-0.22	0.66	0.04	0.09	-0.17		-0.43	0.38	-0.31	0.36	-0.57	-0.61
Common Stock	0.97	0.22	0.69	0.69	0.07	-0.81	0.83	0.57	0.29	-0.03	0.59	-0.48	-0.21	-0.37	0.93	-0.32	0.37	0.42	0.91	-0.43		-0.36	0.16	-0.9	0.69	0.87
Short Term Debt	-0.26	0.02	-0.26	-0.31	0.79	0.15	-0.18	-0.25	0.09	-0.05	-0.18	0.05	0.29	0.1	-0.3	0.65	-0.21	-0.31	-0.13	0.38	-0.36		-0.12	0.28	-0.57	-0.55
Current Deferred Revenue	0.2	-0.31	0.09	0.01	0.11	-0.27	0.11	0.04	-0.04	0.48	-0.21	-0.34	0.45	-0.33	0.04	-0.34	0.11	0.48	0.07	-0.31	0.16	-0.12		-0.13	0.39	0.34
Retained Earnings	-0.89	-0.18	-0.87	-0.79	-0.13	0.91	-0.81	-0.76	-0.32	0.13	-0.64	0.42	0.3	0.31	-0.9	0.25	-0.3	-0.53	-0.88	0.36	-0.9	0.28	-0.13		-0.58	-0.75
Intangible Assets	0.67	-0.19	0.31	0.53	-0.23	-0.55	0.58	0.24	0.03	0.27	0.15	-0.62	0.14	-0.48	0.48	-0.61	0.41	0.22	0.4	-0.57	0.69	-0.57	0.39	-0.58		0.87
Other Liab	0.82	-0.08	0.54	0.66	-0.17	-0.71	0.62	0.46	0.06	0.04	0.31	-0.5	-0.13	-0.47	0.7	-0.58	0.47	0.36	0.63	-0.61	0.87	-0.55	0.34	-0.75	0.87

Click cells to compare fundamentals

Krebs Biochemicals Account Relationship Matchups

Krebs Biochemicals fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Common Stock Shares Outstanding	16.6M	18.0M	19.6M	21.6M	24.8M	15.6M
Total Assets	1.3B	1.6B	1.9B	1.7B	1.8B	1.3B
Short Long Term Debt Total	812.1M	1.1B	1.4B	1.8B	2.4B	2.5B
Other Current Liab	165.0M	274.2M	148.1M	237.0M	326.9M	343.2M
Total Current Liabilities	431.3M	481.9M	780.6M	491.0M	618.3M	539.4M
Total Stockholder Equity	(250.0M)	(427.3M)	(750.9M)	(994.6M)	(1.2B)	(1.1B)
Property Plant And Equipment Net	1.1B	1.3B	1.4B	1.5B	1.5B	1.1B
Net Debt	811.6M	998.4M	580.7M	1.8B	2.4B	2.5B
Accounts Payable	200.3M	207.8M	379.1M	152.8M	189.7M	207.4M
Cash	560K	7.1M	324K	858K	1.4M	1.3M
Non Current Assets Total	1.1B	1.4B	1.5B	1.6B	1.6B	1.4B
Non Currrent Assets Other	54.6M	57.0M	(1K)	51.5M	89.6M	169.8M
Cash And Short Term Investments	560K	10.8M	324K	3.7M	1.4M	1.3M
Net Receivables	2.8M	3.0M	19.5M	6.5M	47.3M	66.4M
Liabilities And Stockholders Equity	1.3B	1.6B	1.9B	1.7B	1.8B	1.3B
Non Current Liabilities Total	1.2B	1.5B	1.9B	2.3B	2.4B	1.3B
Inventory	150.0M	166.0M	255.6M	119.5M	102.4M	145.7M
Other Current Assets	34.1M	34.4M	79.5M	29.7M	23.3M	32.0M
Other Stockholder Equity	1.1B	(623.5M)	1.2B	1.3B	1.5B	1.6B
Total Liab	1.6B	2.0B	2.6B	2.7B	3.0B	1.8B
Total Current Assets	188.6M	214.2M	354.9M	160.6M	174.4M	278.7M
Accumulated Other Comprehensive Income	(1.3B)	(1.4B)	152.2M	110.5M	114.4M	120.2M
Common Stock	166.3M	180.0M	196.2M	215.6M	247.9M	154.5M
Short Term Debt	11.6M	105.9M	101.7M	101.2M	101.8M	128.9M
Current Deferred Revenue	110.5M	(105.9M)	151.8M	115.4M	132.7M	121.4M
Retained Earnings	(1.5B)	(1.8B)	(2.3B)	(2.5B)	(2.7B)	(2.6B)
Intangible Assets	37.7M	35.1M	28.7M	26.9M	25.0M	27.7M
Other Liab	515.7M	501.6M	532.1M	539.0M	619.9M	439.3M
Net Tangible Assets	(161.4M)	(268.4M)	(445.8M)	(769.4M)	(692.5M)	(657.8M)
Other Assets	73.8M	96.0M	82.5M	27.1M	24.4M	23.2M
Long Term Debt	655.1M	1.0B	1.3B	1.7B	1.8B	1.9B
Deferred Long Term Liab	21.8M	19.2M	16.6M	10.2M	9.2M	8.8M
Short Long Term Debt	7.1M	105.9M	99.9M	99.9M	99.3M	113.0M
Property Plant Equipment	1.1B	1.3B	1.4B	1.5B	1.7B	1.1B
Long Term Debt Total	655.1M	1.0B	1.3B	1.7B	2.0B	2.1B
Cash And Equivalents	4.2M	147M	0.0	(1K)	(900.0)	(855.0)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

V	Visa Class A
GOOG	Alphabet Inc Class C
GOOG	Alphabet Inc Class C

Other Information on Investing in Krebs Stock

Balance Sheet is a snapshot of the financial position of Krebs Biochemicals and at a specified time, usually calculated after every quarter, six months, or one year. Krebs Biochemicals Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Krebs Biochemicals and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Krebs currently owns. An asset can also be divided into two categories, current and non-current.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Krebs Net Income From Continuing Ops vs Operating Income Analysis

Net Income From Continuing Ops vs Operating Income

Net Income From Continuing Ops vs Operating Income Correlation Analysis

Correlation Coefficient

Net Income From Continuing Ops

Operating Income

Krebs Biochemicals fundamental ratios Correlations

Krebs Biochemicals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Krebs Biochemicals fundamental ratios Accounts

Also Currently Popular

Other Information on Investing in Krebs Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Common Stock	+ 0.97	Common Stock Shares Outstanding
Total Liab	+ 0.97	Non Current Liabilities Total
Net Debt	+ 0.95	Short Long Term Debt Total
Common Stock	+ 0.93	Non Current Liabilities Total
Retained Earnings	+ 0.91	Total Stockholder Equity
Common Stock	+ 0.91	Total Liab

Retained Earnings	- 0.9	Common Stock
Retained Earnings	- 0.9	Non Current Liabilities Total
Retained Earnings	- 0.89	Common Stock Shares Outstanding
Retained Earnings	- 0.88	Total Liab
Retained Earnings	- 0.87	Short Long Term Debt Total
Total Stockholder Equity	- 0.85	Common Stock Shares Outstanding